Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CABA

Cabaletta Bio Inc

Dec 12 • 10:30AM ET

3.09

Dollar change +0.02
Percentage change 0.65	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BLUE BMRN EDIT TGTX NTLA ALLO SGMO ANIX ADAP

| Held by: VTI IWM VXF IWN IBB VTWO VHT IWC IWO ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.16	Insider Own	15.37%	Shs Outstand	48.85M	Perf Week	-5.08%
Market Cap	150.79M	Forward P/E	-	EPS next Y	-2.62	Insider Trans	0.00%	Shs Float	41.36M	Perf Month	-28.26%
Income	-104.16M	PEG	-	EPS next Q	-0.64	Inst Own	75.15%	Short Float	10.89%	Perf Quarter	-24.94%
Sales	0.00M	P/S	-	EPS this Y	-40.17%	Inst Trans	-6.66%	Short Ratio	2.00	Perf Half Y	-75.44%
Book/sh	3.57	P/B	0.86	EPS next Y	-13.13%	ROA	-55.16%	Short Interest	4.50M	Perf Year	-82.98%
Cash/sh	3.74	P/C	0.82	EPS next 5Y	-	ROE	-62.16%	52W Range	1.76 - 26.35	Perf YTD	-86.41%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-26.63%	ROI	-57.38%	52W High	-88.29%	Beta	2.38
Dividend TTM	-	Quick Ratio	8.11	Sales past 5Y	0.00%	Gross Margin	-	52W Low	75.28%	ATR (14)	0.48
Dividend Ex-Date	-	Current Ratio	8.11	EPS Y/Y TTM	-25.02%	Oper. Margin	-	RSI (14)	46.25	Volatility	9.21% 18.25%
Employees	103	Debt/Eq	0.09	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	22.10
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	-65.49%	Payout	-	Rel Volume	0.78	Prev Close	3.07
Sales Surprise	-	EPS Surprise	-3.99%	Sales Q/Q	-	Earnings	Nov 14 BMO	Avg Volume	2.25M	Price	3.09
SMA20	3.77%	SMA50	-17.21%	SMA200	-64.78%	Trades		Volume	343,066	Change	0.65%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-10-24	Initiated	UBS	Buy	$10
Feb-05-24	Initiated	Jefferies	Buy	$36
Nov-29-23	Initiated	William Blair	Outperform	$38
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$40
Oct-19-23	Initiated	Stifel	Buy	$31
Sep-05-23	Initiated	Citigroup	Buy	$22
Jul-18-23	Initiated	Guggenheim	Buy	$34
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$3 → $16
Aug-30-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$15 → $3
Dec-08-21	Initiated	Wells Fargo	Overweight	$17
Oct-19-21	Resumed	Morgan Stanley	Overweight	$20
Jun-30-21	Initiated	Mizuho	Buy	$22
Jan-08-21	Initiated	Chardan Capital Markets	Buy	$21
Oct-13-20	Initiated	H.C. Wainwright	Buy	$20
Nov-19-19	Initiated	Morgan Stanley	Overweight	$19
Nov-19-19	Initiated	Evercore ISI	Outperform	$25
Nov-19-19	Initiated	Cowen	Outperform

Show Previous Ratings

Nov-26-24 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in December (GlobeNewswire) +5.68%
Nov-18-24 07:00AM	Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 (GlobeNewswire) -10.89%
Nov-14-24 07:00AM	Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -5.74%
Nov-06-24 08:00AM	Cabaletta Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire) +10.71%
Oct-17-24 03:06PM	State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings (GuruFocus.com)
04:30PM	Loading…
Sep-25-24 04:30PM	Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024 (GlobeNewswire)
Aug-28-24 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-21-24 04:32AM	Several Headwinds Dragged Cabaletta Bio (CABA) in Q2 (Insider Monkey) +20.65%
Aug-08-24 07:00AM	Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -34.37%
Jul-08-24 07:01PM	Cabaletta Bio, Inc. (CABA): Why Are Analysts Loving This Shorted Stock Right Now? (Insider Monkey) +7.23%
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jul-02-24 08:00AM	Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum (GlobeNewswire) -5.38%
Jun-14-24 02:00AM	Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis and RESET-SLE Trials of CABA-201 (GlobeNewswire) -15.13%
May-29-24 08:00AM	Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -5.81%
May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia)
11:54AM	Loading…
May-15-24 11:54AM	CABA Stock Earnings: Cabaletta Bio Misses EPS for Q1 2024 (InvestorPlace) +13.00%
07:00AM	Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-13-24 08:00AM	Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
Mar-23-24 05:31AM	Cabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runway (GuruFocus.com)
Mar-21-24 01:53PM	CABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-20-24 07:00AM	Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis (GlobeNewswire)
Mar-08-24 08:50AM	Jim Cramer's 10 Latest Stock Picks This Week (Insider Monkey)
Feb-27-24 10:11AM	Several Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4 (Insider Monkey)
08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in March (GlobeNewswire)
Feb-01-24 04:30PM	Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis (GlobeNewswire) +7.05%
Jan-31-24 08:00AM	Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-08-24 07:00AM	Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis (GlobeNewswire) +8.70%
Jan-02-24 08:00AM	Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 08:49PM	Cabaletta Bio Stock (NASDAQ:CABA): Analysts Expect More Gains Despite Massive Rally (TipRanks) +7.14%
04:30PM	Loading…
Nov-28-23 04:30PM	Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) -26.79%
Nov-09-23 08:10AM	Cabaletta Bio Inc (CABA) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com)
07:00AM	Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-23 08:15AM	Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabalettas CD19-CAR T Cell Therapy on Cellares Cell Shuttle Platform (Business Wire)
07:00AM	Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis (GlobeNewswire)
Oct-30-23 08:00AM	Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November (GlobeNewswire) +7.50%
Oct-09-23 09:40AM	Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year? (Zacks) +5.70%
Oct-02-23 09:14AM	QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software (Zacks)
07:00AM	Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201 (GlobeNewswire)
Oct-01-23 11:00AM	Top Stocks for October 2023 (Investopedia)
Sep-25-23 08:50AM	What Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing' (Zacks)
Sep-19-23 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in September (GlobeNewswire) -6.92%
Sep-01-23 02:00PM	Top Growth Stocks for September 2023 (Investopedia) -5.93%
11:30AM	Top Stocks for September 2023 (Investopedia)
Aug-31-23 09:55AM	Wall Street Analysts Believe Cabaletta Bio, Inc. (CABA) Could Rally 41.61%: Here's is How to Trade (Zacks)
08:30AM	The 7 Most Promising Momentum Stocks to Own Now (InvestorPlace)
Aug-30-23 08:00AM	Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September (GlobeNewswire)
Aug-25-23 10:13AM	Lab Notes: Wistar, Coriell researchers identify potential target for gastric cancers treatment (American City Business Journals)
Aug-23-23 08:50AM	Recent Price Trend in Cabaletta Bio, Inc. (CABA) is Your Friend, Here's Why (Zacks)
Aug-22-23 08:00AM	Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201 (GlobeNewswire)
Aug-15-23 01:46PM	Does Cabaletta Bio, Inc. (CABA) Have the Potential to Rally 27.85% as Wall Street Analysts Expect? (Zacks)
Aug-10-23 07:00AM	Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-23 10:00AM	Top Stocks for August 2023 (Investopedia) -7.27%
Jul-24-23 08:00AM	Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors (GlobeNewswire) -6.68%
Jul-18-23 02:58PM	Why Shares of Cabaletta Bio Are Up Tuesday (Motley Fool) +11.93%
Jun-20-23 08:00AM	Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors (GlobeNewswire) -5.26%
Jun-08-23 11:14AM	Top Healthcare Stocks for June 2023 (Investopedia)
May-31-23 08:00AM	Cabaletta Bio to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-24-23 07:33AM	Institutional investors in Cabaletta Bio, Inc. (NASDAQ:CABA) lost 18% last week but have reaped the benefits of longer-term growth (Simply Wall St.)
May-22-23 04:30PM	Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares (GlobeNewswire)
May-17-23 10:16PM	Cabaletta Bio Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -7.83%
04:01PM	Cabaletta Bio Announces Proposed Public Offering of Common Stock (GlobeNewswire)
May-16-23 07:00AM	Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis (GlobeNewswire) +14.63%
May-11-23 08:39AM	Top Healthcare Stocks for May 2023 (Investopedia) +6.67%
07:00AM	Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-02-23 04:35PM	Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting (GlobeNewswire) +5.70%
May-01-23 07:00AM	Cabaletta Bio Receives FDA Fast Track Designation for CABA-201 (GlobeNewswire) +9.83%
Apr-25-23 01:07PM	Great news for Cabaletta Bio, Inc. (NASDAQ:CABA): Insiders acquired stock in large numbers last year (Simply Wall St.) -5.94%
08:00AM	Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ (GlobeNewswire)
Apr-13-23 04:30PM	Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-31-23 07:00AM	Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus (GlobeNewswire) +16.48%
Mar-16-23 07:00AM	Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-14-23 07:14AM	We're Keeping An Eye On Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate (Simply Wall St.) +8.02%
Feb-28-23 08:00AM	Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-19-23 10:53AM	TipRanks Perfect 10 List: Theres an Opportunity Brewing in These 2 Stocks (TipRanks)
Feb-17-23 06:43PM	12 Most Promising Micro-Cap Stocks According to Analysts (Insider Monkey)
Feb-06-23 12:00PM	Here's Why Cabaletta Bio, Inc. (CABA) is a Great Momentum Stock to Buy (Zacks)
Jan-31-23 09:40AM	Is Aurora Cannabis (ACB) Outperforming Other Medical Stocks This Year? (Zacks) +6.37%
Jan-09-23 07:00AM	Autolus Therapeutics Announces Collaboration with Cabaletta Bio for Use of Autolus Safety Switch System in Cell Therapies for Autoimmune Disease (GlobeNewswire) +6.04%
Jan-05-23 08:00AM	Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-03-23 05:40AM	The Zacks Analyst Blog Highlights AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences (Zacks)
Dec-30-22 09:03AM	4 Drug Stocks That More Than Doubled This Year (Zacks)
Dec-23-22 09:40AM	Is Neuronetics (STIM) Stock Outpacing Its Medical Peers This Year? (Zacks) -8.82%
Dec-13-22 11:41AM	Cabaletta Bio, Inc.'s (NASDAQ:CABA) largest shareholders are individual investors who were rewarded as market cap surged US$15m last week (Simply Wall St.)
Dec-12-22 01:37PM	Cabaletta Bio expects to complete $35M stock and warrant sale this week to advance cell therapy candidate (American City Business Journals) -7.72%
Dec-08-22 07:00AM	Cabaletta Bio Announces $35 Million Offering (GlobeNewswire)
Dec-07-22 09:55AM	Can Cabaletta Bio, Inc. (CABA) Climb 60% to Reach the Level Wall Street Analysts Expect? (Zacks) +10.40%
Nov-22-22 08:00AM	Cabaletta Bio to Present at the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +7.16%
Nov-16-22 11:26AM	As Cabaletta Bio, Inc. (NASDAQ:CABA) hits US$104m market cap, insiders may be dismayed about not purchasing higher quantities (Simply Wall St.) +5.88%
Nov-10-22 07:00AM	Cabaletta Bio Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Oct-11-22 10:06AM	IASO Biotherapeutics, Cabaletta Bio Ink License Pact For CD19 Binder (Benzinga)
07:00AM	Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases (GlobeNewswire)
Oct-06-22 08:00AM	Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene & Cell Therapy (GlobeNewswire)
Oct-05-22 06:26AM	Will Cabaletta Bio (NASDAQ:CABA) Spend Its Cash Wisely? (Simply Wall St.)
Sep-26-22 08:00AM	Cabaletta Bio to Present at the Chardan 6th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-10-22 07:00AM	Cabaletta Bio Presents New Interim Data from the DesCAARTes Phase 1 Trial at the 31st EADV Congress (GlobeNewswire)
Sep-06-22 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-29-22 01:58PM	Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes Trial (GlobeNewswire) -33.95%
Aug-11-22 07:00AM	Cabaletta Bio Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +13.28%
Jun-09-22 12:00PM	What Makes Cabaletta Bio, Inc. (CABA) a New Buy Stock (Zacks)

Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Binder Gwendolyn	See Remarks	Jan 19 '24	Option Exercise	1.01	11,000	11,110	31,000	Jan 19 06:30 PM
Binder Gwendolyn	See Remarks	Jan 19 '24	Sale	19.59	11,000	215,439	20,000	Jan 19 06:30 PM
Binder Gwendolyn	See Remarks	Dec 19 '23	Option Exercise	1.01	11,000	11,110	31,000	Dec 19 08:37 PM
Binder Gwendolyn	See Remarks	Dec 19 '23	Sale	21.89	11,000	240,789	20,000	Dec 19 08:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CABA

Cabaletta Bio Inc

Upgrade your FINVIZ experience